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Veterinary Vaccines: 
Report:  James A. Roth and Paul-Pierre Pastoret 
 
Infectious diseases of animals are greatly increasing in importance.  The rapid rise in global human 
population requires ever increasing production of food derived from animal agriculture and 
aquaculture.  Increasing human and agricultural animal populations and the resulting environmental 
degradation are leading to the emergence of new infectious diseases and the re-emergence of 
diseases that were on the decline.  Many of these emerging and re-emerging diseases are zoonotic 
and are significant threats to human health globally.  Novel veterinary vaccines are needed to 
enhance food production, to protect humans from exposure to zoonotic diseases, and to reduce 
animal suffering.  Safe and effective vaccines exist for some animal diseases, but for many 
important animal diseases, conventional approaches to vaccine development have not been 
successful.  The premise of this meeting of leading academic, government and industry 
immunologists is that basic research on pathogen biology, virulence mechanisms, innate and 
acquired immunity, antigen processing and presentation, host pathogen interaction and adjuvants 
will lead to new breakthroughs in vaccine discovery and development.   
 
Basic research is essential to discover novel vaccine approaches.  The fields of immunology, 
microbial physiology, molecular biology and vaccinology are advancing rapidly, presenting many 
opportunities to use new and powerful molecular tools to investigate both pathogen virulence 
mechanisms and host response and to apply basic research advances to the development of novel 
veterinary vaccines.  However, there are significant challenges to the development of novel 
vaccines.  Funding is severely limited, there are not enough scientists currently working in 
veterinary vaccine development, and there are insufficient biosecure research facilities to safely test 
potential products.  Because resources are limited, researchers need to focus on the highest priorities 
that will have the greatest potential impact.  This research should be conducted with the end goal in 
mind of development of safe and effective vaccines.   
 
The greatest advances will occur if government, academic and industry scientists and resources are 
all brought to bear on the problem of novel vaccine discovery and development.  Government 
resources are needed to fund basic research and to set priorities, especially for vaccines to protect 
against imported or emerging diseases.  Academic and government scientists are an excellent 
resource for conducing much of the basic research.  Participation of the vaccine industry is essential 
to carry out the final development, production, and distribution of vaccines.  These types of 
partnerships have already lead to licensed biotechnology-derived veterinary vaccines, including 
recombinant antigen vaccines, gene deleted vaccines, live recombinant vaccines, DNA vaccines, 
and transgenic plant derived vaccines.  
 
There are many commercially available vaccines for animal diseases, including over 1,300 vaccines 
licensed for animal use covering 180 disease agents in the U.S. alone.  Most of these are 
conventionally produced live or killed vaccines for acute viral or bacterial diseases.  Many of these 
vaccines do not have an optimal safety and efficacy profile.  Improved vaccines for these diseases 
depend on a more complete understanding of host pathogen interaction and immune responses.  
 
Very few vaccines are available for chronic viral or bacterial diseases or for mycoplasmal diseases, 
rickettsial diseases, chlamydial diseases, fungal diseases, protozoal diseases, parasitic diseases, and 
neoplastic diseases.  These are more difficult targets for vaccine development and require basic 
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research to lead to successful vaccine strategies.  Development of vaccines for these diseases could 
lead to dramatic improvements in human and animal health and food production.   
 
Protective immunity to these complex organisms is likely to require vaccines which stimulate 
multiple arms of the acquired immune system to defend against a variety of pathogenic immune 
evasion mechanisms (Figure 1).  Genetic variability in the infectious agents and in the host species 
further complicates the development of broadly effective vaccines.  It is essential to understand the 
host pathogen interaction from the first moments of infection.  Early interactions with innate 
immune mechanisms have a major influence on the types of acquired immunity induced and 
provide opportunities to influence vaccine safety and efficacy. 
 
Figure 1
Pathogenic Mechanisms
• Adherence to Mucosa
• Invasive parasite
• Exotoxin/Endotoxin
• Viremia
• Septicemia
• Intracytoplasmic Growth
• Growth in phagosome
• Rapid viral replication
• Infect epithelial cells
Defense Mechanisms
• Mucosal Antibody (IgA)
• IgE
• Neutralizing Antibody
• Neutralizing Antibody
• Opsonizing Antibody
• Cytotoxic T cells
• TH1 Cytokines
• Types 1 and 2 interferon
• Gamma Delta T cells
Stimulation of Multiple Defense Mechanisms 
to Improve Efficacy
 
 
 
There are a number of diseases for which safe and effective vaccines do not exist.  In some cases, 
attempts to produce vaccines have not been successful, and in other cases no attempt to develop 
commercially available vaccines has been made because the market potential is not sufficient for 
the investment needed.  This is especially true for vaccines that protect against foreign animal 
disease incursion or the emergence of novel pathogens.  If there is not an existing market for a 
vaccine, it is essential for government agencies to fund the development and stockpiling of vaccines 
for emergency use.  This requires foresight and commitment on the part of national governments.  
 
In addition to the potential market for a product, other limitations to improving animal vaccines 
through new technologies include the high cost for research, development and manufacturing. 
Public concern about genetically engineered organisms is a factor in some countries.  Industry has 
concerns about proprietary rights to technology.  In addition, in some cases, a restrictive regulatory 
environment surrounding research and development on select agents and foreign animal disease 
agents also limits development of animal vaccines. 
 
- 18 - 
Most national governments do not produce and distribute veterinary vaccines.  Therefore, vaccines 
will only be available if private industry can recover their costs plus a reasonable profit.  This may 
result from vaccine sales or from government investment in vaccine development and distribution.  
National government or international agency investment is essential if vaccines that do not have a 
viable market are to be made available for high priority transboundary diseases.  This includes 
diseases that are foreign to a particular country, and diseases which limit animal production in 
developing nations without the resources to purchase animal vaccines.  Countries which enjoy 
freedom from important transboundary diseases must invest in controlling diseases in developing 
countries because this greatly reduces the threat of incursion of disease into developed countries.   
 
An intentional outbreak due to biological or agro terrorism will create an emergency situation in a 
completely naïve population of animals.  Vaccines will be essential tools to control the outbreak and 
reduce the need for mass slaughter of animals.  The expected performance from a vaccine under 
these conditions will differ from that expected from a vaccine used for mass vaccination during 
“peace time” in a population regularly exposed to similar antigens.  
 
Vaccines to be used to assist in the control of foreign animal disease outbreaks will first of all have 
to confer a rapid onset of protection in the animal after one dose is given.  This may be 
accomplished by acting on innate immune mechanisms before the adaptive immune mechanisms 
can respond.  Secondly, whenever possible, vaccines for emergency control of a foreign animal 
disease outbreak should confer, if not a sterile immunity, at least herd immunity in order to 
dramatically reduce the transmission of the infectious agent.  When attempting to control an 
outbreak of a highly contagious animal disease it is more important to stop the spread of the disease 
than to prevent clinical signs.  The efficacy of the vaccine becomes more important than minor 
safety concerns in order to have an epidemiological impact to reduce spread of infection. 
 
Vaccines for emergency animal disease control should confer a broad range of protection, 
especially, when facing outbreaks of infections with highly variable pathogens.  Whenever possible, 
these vaccines should be DIVA (differentiation of infected from vaccinated animals) compatible, in 
order to improve surveillance by allowing the detection of vaccinated animals that have become 
infected and may be carriers.  
 
The duration of protection conferred by a foreign animal disease vaccine is less important since the 
vaccinated animals will either be slaughtered at the end of the outbreak or will not need to be 
protected because the infectious agent will hopefully be eliminated.  The presence of seropositive 
animals may also be a disadvantage for surveillance programs later on. 
 
The recommendations coming from this meeting hold great promise for the development of novel 
animal vaccines, which could improve animal health, reduce the potential for humans to contract 
zoonotic diseases, increase the efficiency of food production and protect agricultural economies 
from incursion of foreign animal diseases.  
